Oncocyte VitaGraft Kidney Study Results Published In The New England Journal Of Medicine
$OCX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
- Late-breaking presentation of data at American Transplant Congress on Monday, June 3
- Data show potential to monitor for therapeutic efficacy and recurrence
- Potential repeat testing opportunities with claims expansion
IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.